- Home
- AMBI vs TCRX Comparison
AMBI vs TCRX Comparison
Compare AMBI & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBI
- TCRX
- Stock Information
- Founded
- AMBI 1995
- TCRX 2018
- Country
- AMBI Brazil
- TCRX United States
- Employees
- AMBI N/A
- TCRX N/A
- Industry
- AMBI Environmental Services
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- AMBI Industrials
- TCRX Health Care
- Exchange
- AMBI Nasdaq
- TCRX Nasdaq
- Market Cap
- AMBI 321.5M
- TCRX 257.5M
- IPO Year
- AMBI N/A
- TCRX 2021
- Fundamental
- Price
- AMBI $5.27
- TCRX $4.06
- Analyst Decision
- AMBI
- TCRX Strong Buy
- Analyst Count
- AMBI 0
- TCRX 5
- Target Price
- AMBI N/A
- TCRX $11.40
- AVG Volume (30 Days)
- AMBI 15.7K
- TCRX 260.3K
- Earning Date
- AMBI 01-01-0001
- TCRX 11-12-2024
- Dividend Yield
- AMBI N/A
- TCRX N/A
- EPS Growth
- AMBI 3161.09
- TCRX N/A
- EPS
- AMBI 0.56
- TCRX N/A
- Revenue
- AMBI $504,573,816.00
- TCRX $9,362,000.00
- Revenue This Year
- AMBI N/A
- TCRX N/A
- Revenue Next Year
- AMBI N/A
- TCRX $3.10
- P/E Ratio
- AMBI $9.04
- TCRX N/A
- Revenue Growth
- AMBI 25.13
- TCRX N/A
- 52 Week Low
- AMBI $3.07
- TCRX $3.73
- 52 Week High
- AMBI $8.44
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- AMBI 45.44
- TCRX 31.07
- Support Level
- AMBI $4.84
- TCRX $4.03
- Resistance Level
- AMBI $5.97
- TCRX $6.23
- Average True Range (ATR)
- AMBI 0.81
- TCRX 0.39
- MACD
- AMBI -0.16
- TCRX -0.13
- Stochastic Oscillator
- AMBI 31.54
- TCRX 4.33
About AMBI Ambipar Emergency Response
Ambipar Emergency Response is a environmental, emergency response and industrial field service provider in Brazil with presence in 16 countries in Latin America, North America, Europe, Africa and Antarctica. The company provides customers with a full suite of environmental services organized around prevention, training and emergency response on all transportation modes. The portfolio includes a broad variety of services such as environmental remediation, industrial field services, industrial cleaning of chemical and non-chemical products and of hazardous and non-hazardous waste, consulting services focused on accident prevention and environmental licensing.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.